Ivan Bergstein, M.D. Chief Executive Officer	Dr. Bergstein has served as Stemline's CEO since its inception in 2003. Formerly, Dr. Bergstein was Medical Director of Access Oncology, Inc., a private clinical stage oncology-focused biotechnology company, where he was a key member of the founding team that built the company's clinical pipeline and ultimately transitioned the company into its acquirer, Keryx Biopharmaceuticals (Nasdaq: KERX). Prior to this, he was senior biopharmaceuticals analyst at a Wall Street-based firm, Cancer Advisors Inc., which advised investment funds on public oncology-focused companies. He received a B.A. in mathematics from the University of Pennsylvania and an M.D. from the Mount Sinai Medical Center where he completed a general surgery internship. Subsequently, he was named the Jerome A. Urban post-doctoral fellow at Cornell University Medical College. Dr. Bergstein then went on to complete a residency in internal medicine and clinical fellowship in hematology-medical oncology at the New York Presbyterian Hospital-Weill Medical College of Cornell University where he is currently a voluntary faculty member.
Thomas P. Cirrito, Ph.D. Director of Operations	Prior to joining Stemline, Dr. Cirrito was a biopharmaceuticals equities analyst at Piper Jaffray, where he covered large and small cap biotechnology companies. Previously he was a life sciences consultant for A.G. Edwards Capital Partners, a venture capital group . He received a B.A. in Biological Sciences and a Ph.D. in Immunology from Washington University (St. Louis, MO).

Geoffrey Yarranton, Ph.D.
Chief Scientific Officer
Kalobios Pharmaceuticals, Inc. (Palo Alto, CA)

Francis Giles, M.D.
University of Texas Health Science Center (San Antonio, TX)

Fred Appelbaum, M.D.
Fred Hutchinson Cancer Center (Seattle, WA)

Charles Schiffer, M.D.
Wayne State University (Detroit, MI)